


EA2186 - A Randomized Phase II Study of  
Gemcitabine and Nab-Paclitaxel Compared  
with 5 Fluorouracil and Liposomal Irinotecan  
in Older Patients with Treatment Naïve  
Metastatic Pancreatic Cancer (*G/ANT*)

Efrat Dotan, MD, MTR

Fox Chase Cancer Center

July 2020

# EA2186 - Study Design Randomized Phase II



**Stratification:**  
ECOG 0-1 vs. 2.  
Age 70-75 vs. >75

Primary end point of randomized portion – OS  
Secondary end points for randomized portion – PFS, Toxicity; AE specific to the older adults.

| Domain                                 | Screening Geriatric Assessment   | Score range         | Fit - <u>no</u> GA abnormalities                                 | Vulnerable- <u>any</u> mild-moderate GA abnormalities         | Frail- <u>any</u> severe GA abnormalities                    |
|--|--|---------------------|--|---|--|
| <b>Functional status<sup>1</sup></b>   | ADL<br>IADL  | 0-6<br>0-8 F/ 0-5 M | 6<br>8F/5M   | 5<br>6-7F/4M  | ≤4<br><5F/≤3M  |
| <b>Co-morbidities<sup>2</sup></b>      | CIRS-G   |                     | No score 3-4<br><b>AND</b><br><5 comorbidities with a score of 2 | No score 3-4 <b>AND</b><br><8 comorbidities with a score of 2 | ≥1 score 3-4 <b>OR</b><br>>8 comorbidities with a score of 2 |
| <b>Cognition<sup>3</sup></b>           | Blessed Orientation<br>Memory<br>Concentration<br>Test   | 0-28                | 0-4  | 5-10  | ≥11  |
| <b>Age<sup>2*</sup></b>                |  |                     |  | ≥80   |  |
| <b>Geriatric Syndromes<sup>4</sup></b> | <ul style="list-style-type: none"> <li>Repeated Falls (&gt;3 in 6m)</li> <li>Urinary/Fecal incontinence</li> </ul> |                     | None   | None  | Presence of any of these would exclude patients              |

<sup>1</sup>Corre et al. JCO 2016

<sup>2</sup>Tucci et al; Leukemia and Lymphoma 2015.

<sup>3</sup> Mohile et al; JCO 2018.

<sup>4</sup>GrantPax study - Betge et al. BMC 2018

# Eligibility:

**Open eligibility to ensure accrual of real world patients!**

- **Newly diagnosed metastatic pancreatic cancer**
- **≥70 year old with ECOG 0-2**
- **Vulnerable on the screening tool.**
- **Adequate organ function (hematologic, hepatic, renal)**
- **Ability to understand and provide informed consent**

# Primary Objective:

- Overall survival
- 3.8 month improvement in OS (7.7 months to 10.7 months)
- One sided alpha 0.10 and 80% power
- Sample size – 92 patients per arm (total 184)

## Secondary Objectives:

- Progression Free survival (PFS), Response Rate (RR)
- Comprehensive geriatric assessments as predictors of toxicity and outcomes
- Rates of toxicities that are of interest for older patients

# Elderly Specific Toxicities:

| <b>Any Grade 5 Toxicity</b> | <b>Grade 4 Toxicity</b>   | <b>Grade 3 or higher toxicity</b>        | <b>Elderly specific toxicities of concern</b>  |
|-----------------------------|---|--|--|
|                             | <b>Thrombocytopenia<br/>Febrile neutropenia<br/>Infection<br/>Peripheral neuropathy (grade 2)</b> | <b>Bleeding<br/>Diarrhea<br/>Fatigue</b> | <b>Deterioration of PS<br/>Falls<br/>ER visits<br/>Hospitalization<br/>Dose reductions<br/>Treatment discontinuation</b> |

| Geriatric /QOL Assessment Tools                      | Assessment        | Administered by | Assessment timing |                    |
|--|-------------------|-----------------|-------------------|--------------------|
|  |                   |                 | Pre-tx            | Disease evaluation |
| Activities of Daily Living subscale (ADL)            | Functional status | Patient         | X                 | X                  |
| ECOG PS  |                   | MD              | X                 |                    |
| Instrumental Activities of Daily Living (IADL)       |                   | Patient         | X                 | X                  |
| # of falls in the past 6 months                      |                   | CRC             | X                 |                    |
| Cumulative Illness Rating Scale – Geriatric (CIRS-G) | Comorbidity       | CRC             | X                 |                    |
| Pre-treatment Body Mass Index (BMI)                  | Nutrition         | CRC             | X                 |                    |
| Weight loss over 6 months                            |                   | Patient         | X                 |                    |
| Mini Nutritional Assessment (MNA)                    |                   | CRC             | X                 |                    |
| Geriatric Depression Scale                           | Depression        | Patient         | X                 |                    |
| Blessed Orientation Memory Concentration Test        | Cognition         | CRC             | X                 |                    |
| FACT-Hep (Version 4)                                 | QOL               | Patient         | X                 | X                  |
| Estimated time of evaluation GA + QOL                |                   |                 | ~20 min           | ~5-10min           |

# CORELATIVE STUDIES

## **Sarcopenia:**

- CT images will be used to evaluate total abdominal muscles mass
- We will determine the association of baseline CT measurements of muscle and adipose tissue with treatment tolerance, PFS and OS.
- Central review of images

## **Biomarkers of aging:** IL6, CRP

Banking of peripheral blood for future studies.

**Fitness trackers-** for assessment of “true” performance status, association with outcomes – proposal under review.

**EA2186 was activated  
on June 18, 2020.**

**Thanks for promoting  
the study at your  
institutions.**

